Federal contract award
89243223CNE000030
HIGH ASSAY LOW ENRICHED URANIUM (HALEU) CASCADE DEMO COMPLETION AND EXTENDED PRODUCTION
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Energy |
| Office | IDAHO OPERATIONS OFFICE |
| NAICS | 221113 — Nuclear Electric Power Generation |
| PSC | 4470 — Nuclear Reactors |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST SHARING |
| Obligations | $332.0M |
| Current contract value | $332.4M |
| Potential contract value / ceiling | $1.1B |
| Start date | Nov 30, 2022 |
| Current end date | Sep 30, 2026 |
| Potential end date | Jun 30, 2028 |
| Latest award activity | Jun 30, 2026 |
| Source loaded | Sep 19, 2026 |
Funding and modification history
Showing the latest 28 of 28 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Jun 30, 2026 | P00027 | $15.0M | THE PURPOSE OF THIS AMENDMENT TO THE CONTRACT IS TO: EXERCISE THE MODIFIED CLIN 0008 (OPTION PERIOD 1B), WHICH IS 3-MONTHS CASCADE MAINTENANCE AND STORE SNM, WITH NO HALEU PRODUCTION. |
| Jan 12, 2026 | P00026 | $875.3K | THE PURPOSE OF THIS AMENDMENT IS TO APPROVE AND FUND MULTIPLE CHANGE ORDERS. |
| Dec 8, 2025 | P00025 | $0 | THE PURPOSE OF THIS AMENDMENT TO THE CONTRACT IS TO EXTEND THE PHASE 2 PERIOD OF PERFORMANCE FROM OCTOBER 31, 2025, TO JANUARY 31, 2026. |
| Aug 20, 2025 | P00024 | $1.6M | THE PURPOSE OF THIS AMENDMENT TO THE CONTRACT IS TO AUTHORIZE MULTIPLE CHANGE ORDERS, APPROVE A NEW CBA AGREEMENT, AND EXTEND THE PHASE 2 PERIOD OF PERFORMANCE. |
| Jun 18, 2025 | P00023 | $108.0M | INCREMENTALLY FUND CLIN 0002 IN THE AMOUNT OF $11,049.88. INCREMENTALLY FUND CLIN 0003 IN THE AMOUNT OF $107,993,746.00. |
| Jun 17, 2025 | P00022 | $0 | MODIFY AND EXERCISE OPTION PERIOD BY SPLITTING IT UP BETWEEN TWO CLINS, FROM A 3-YEAR OPTION PERIOD UNDER ONE CLIN TO A ONE AND TWO-YEAR OPTION PERIOD UNDER TWO SEPARATE CLINS. |
| Jun 13, 2025 | P00021 | $8.2M | AUTHORIZE MOVING SCOPE FROM CLIN 003 TO CLIN 002 TO PURCHASE THE LEU FEED CYLINDER THEY NEED FOR PHASE 3 PRODUCTION IN NOVEMBER 2025, PROCURING ADDITIONAL WASTE STORAGE, AND INCREMENTAL FUNDING FOR CLIN 002 IN THE AMOUNT OF $8,238,455.24. |
| Jun 3, 2025 | P00020 | $8.5M | 1. AUTHORIZE CONTINUED PERFORMANCE OF PHASE 2 ACTIVITIES THROUGH JUNE 30, 2025, AND AUTHORIZE LIMITED FUNDING IN THE AMOUNT OF $8,530,292.00 2. PROVIDE INCREMENTAL FUNDING UNDER CLIN 0002 IN THE AMOUNT OF $8,530,292.00 |
| May 5, 2025 | P00019 | $7.6M | 1. AUTHORIZE CONTINUED PERFORMANCE OF PHASE 2 ACTIVITIES THROUGH MAY 31, 2025. 2.PROVIDE INCREMENTAL FUNDING UNDER CLIN 0002 IN THE AMOUNT OF $7,600,000, CHANGING THE TOTAL OBLIGATIONS FOR CLIN 0002 FROM $144,722,536 TO $152,322,536. |
| Mar 31, 2025 | P00018 | $15.7M | THE PURPOSE OF THIS AMENDMENT TO THE CONTRACT IS TO: 1.EXTEND THE DEFINITIZATION DEADLINE DETAILED IN MODIFICATION 017 OF THIS CONTRACT FROM MARCH 31, 2025 TO APRIL 30, 2025. 2.AUTHORIZE CONTINUED PERFORMANCE OF PHASE 2 ACTIVITIES THROUGH 4/30/25 |
| Feb 19, 2025 | P00017 | $0 | 1.EXTEND THE DEFINITIZATION DEADLINE DETAILED IN MODIFICATION 015 OF THIS CONTRACT FROM FEBRUARY 28, 2025, TO MARCH 31, 2025. 2.AUTHORIZE CONTINUED PERFORMANCE OF PHASE 2 ACTIVITIES THROUGH MARCH 31, 2025 WITHIN THE EXISTING COST CEILING |
| Jan 10, 2025 | P00016 | $14.2M | THE PURPOSE OF THIS MODIFICATION IS TO: 1. PROVIDE INCREMENTAL FUNDING TO CLIN 0002 IN THE AMOUNT OF $14,211,340.00, CHANGING THE TOTAL OBLIGATION FROM $114,817,188.00 TO $129,028,528.00. |
| Dec 31, 2024 | P00015 | $0 | THE PURPOSE OF THIS MODIFICATION IS TO: EXTEND THE DEFINITIZATION DEADLINE DETAILED IN MODIFICATION 013 OF THIS CONTRACT FROM DECEMBER 31, 2024, TO FEBRUARY 28, 2025, AND AUTHORIZE AN ADDITIONAL LIMITED COST CEILING INCREASE OF $13,489,552.00(NO FEE |
| Dec 19, 2024 | P00014 | $9.9M | THE PURPOSE OF THIS MODIFICATION IS TO ADD INCREMENTAL FUNDING AND APPROVE FOUR CHANGE ORDERS |
| Nov 5, 2024 | P00013 | $24.1M | 1.EXTEND THE PHASE 2 PERIOD OF PERFORMANCE END DATE FROM NOVEMBER 6, 2024, TO JUNE 30, 2025 |
| Nov 4, 2024 | P00012 | $0 | THE PURPOSE OF THIS AMENDMENT TO: 1. AUTHORIZE THE PURCHASE AND INSTALLATION OF TWO REPLACEMENT PERSONNEL CONTAMINATION MONITORS(PCMS) 2. AUTHORIZE THE PURCHASE OF TEN 5B CYLINDERS 3. AMEND THE CONTRACT TO ADD OPERATIONS SHIFT COORDINATORS(OSC) |
| Aug 14, 2024 | P00011 | $29.3M | THE PURPOSE OF THIS AMENDMENT TO: 1.PROVIDE INCREMENTAL FUNDING TO CLIN 0002 IN THE AMOUNT OF $28,906,490.90 2.PROVIDE INCREMENTAL FUNDING TO CLIN 0006 IN THE AMOUNT OF $345,521.00 3.AUTHORIZE THE INSTALLATION OF ONE REPLACEMENT X-6000 TRANSFORMER |
| Jun 8, 2024 | P00010 | $-5.5M | THE PURPOSE OF THIS AMENDMENT TO THE CONTRACT IS TO: 1. DE-OBLIGATE CLIN 0002 FUNDING IN THE AMOUNT OF -$5,463,616.00 IN ORDER TO COMPLETE THE INTERNAL DOE ACCOUNTING ADJUSTMENT REFERENCED IN MOD 009, CHANGING THE TOTAL OBLIGATION FOR CLIN 0002 FR |
| May 21, 2024 | P00009 | $20.6M | 1. PROVIDE INCREMENTAL FUNDING TO CLIN 0002 IN THE AMOUNT OF $20,627,096.00, CHANGING THE TOTAL OBLIGATION FROM $39,080,875.23 TO $59,707,971.23. NOTE: A SUBSEQUENT AMENDMENT WILL IMMEDIATELY FOLLOW IN ORDER TO DE-OBLIGATE $5,463,616.00 IN FUNDS |
| Apr 29, 2024 | P00008 | $9.8M | PROVIDE INCREMENTAL FUNDING TO CLIN 0002 IN THE AMOUNT OF $9,799,429.60, CHANGING THE TOTAL OBLIGATION FROM $29,281,445.63 TO 39,080,875.23. |
| Apr 4, 2024 | P00007 | $4.8M | PROVIDE INCREMENTAL FUNDING TO CLIN 0002 IN THE AMOUNT OF $4,756,181.53, CHANGING THE TOTAL OBLIGATION FROM $24,525,264.10 TO $29,281,445.63. |
| Dec 27, 2023 | P00006 | $20.6M | 1.OBLIGATE FUNDING TO CLIN 0001 FOR $770,016.87.00, CHANGING THE TOTAL OBLIGATION FROM $28,270,000.00 TO $29,040,016.87. 2.OBLIGATE FUNDING TO CLIN 0007 FOR $19,795,264.10, CHANGING THE TOTAL OBLIGATION FROM $4,730,000.00 TO $24,525,264.10. |
| Oct 19, 2023 | P00005 | $5.5M | 1) OBLIGATE $901,128.00 TO CLIN 00006, CHANGING THE TOTAL OBLIGATION FROM $150,000.00 TO $1,051,128.00. 2) OBLIGATE $4,562,488.00 TO CLIN 00007, CHANGING THE TOTAL OBLIGATION FROM $200,000.00 TO $4,762,488.00. |
| Sep 29, 2023 | P00004 | $350.0K | HIGH ASSAY LOW ENRICHED URANIUM (HALEU) CASCADE DEMO COMPLETION AND EXTENDED PRODUCTION 1.INCREMENTAL FUNDING IN THE AMOUNT OF $23,000,000. $3,730,000 GOING TO CLIN 0002 AND $19,270,000 GOING TO CLIN 0001. |
| Apr 3, 2023 | P00003 | $23.0M | HIGH ASSAY LOW ENRICHED URANIUM (HALEU) CASCADE DEMO COMPLETION AND EXTENDED PRODUCTION 1.INCREMENTAL FUNDING IN THE AMOUNT OF $23,000,000. $3,730,000 GOING TO CLIN 0002 AND $19,270,000 GOING TO CLIN 0001. |
| Mar 21, 2023 | P00002 | $5.0M | 1.INCREMENTAL FUNDING IN THE AMOUNT OF $5,000,000. 2.UPDATE THE PERIOD OF PERFORMANCE START FROM 11/30/22 TO 12/01/22. 3.UPDATE CLAUSE 52.244-2 SUBCONTRACTS 4.APPROVE CLIN 2 ACTIVITIES IN CLIN 1 |
| Jan 19, 2023 | P00001 | $2.8M | HIGH ASSAY LOW ENRICHED URANIUM (HALEU) CASCADE DEMO COMPLETION AND EXTENDED PRODUCTION DE-OBLIGATE $2,203,879 FROM CLIN 0001 AND OBLIGATE $5,000,000 TO CLIN 0001. |
| Nov 30, 2022 | 0 | $2.2M | HIGH ASSAY LOW ENRICHED URANIUM (HALEU) CASCADE DEMO COMPLETION AND EXTENDED PRODUCTION |
Estimated positioning window
Jun 30, 2027 – Dec 30, 2027
Recompete signal: . Rule-based research score; positioning dates are estimates.
55/100
Why this recompete signal
Contract timing and recorded acquisition signals at the time of calculation.
Stored score: 55/100. Available recorded signals: 50 points.
- Contract end 2028-06-30 (607 days from calculation)
- +25 points
- 1 historical awards in this buyer and category group
- +0 points
- 28 recorded award transactions
- +10 points
- Latest award action: 2026-06-30
- +5 points
- Parent award identifier recorded
- +0 points
- Solicitation identifier recorded
- +10 points
- Linked official forecast
- +0 points
- Calculated on
- 2026-11-01 10:17:53.997580+00:00
The historical group combines buyer, NAICS, and PSC. Multiple awards in this group do not by themselves establish repeated competitions.
Rule-based research score; it does not measure your chance of winning.
This older calculation does not retain a complete reproducible breakdown. Missing or changed inputs are not assigned invented points: Original award-value bonus input.
Recompete score calculated Nov 1, 2026.
Buyer contacts from matching notices
Matched on exact award/solicitation identifier and awarding agency. Source dates describe the notice, not current contact verification.
| Contact | Role | Published contact methods | Evidence | Source date |
|---|---|---|---|---|
| Fogg, Jeffrey C. | Contact | FOGGJC@ID.DOE.GOV 208-526-4958 | Source | Aug 17, 2022 |
| Fogg, Jeffrey C. | Contact | FOGGJC@ID.DOE.GOV 208-526-4958 | Source | Jun 29, 2022 |
| Fogg, Jeffrey C. | Contact | FOGGJC@ID.DOE.GOV 208-526-4958 | Source | Jun 28, 2022 |
| Gregory J. Tomlinson | Contact | tomlingj@id.doe.gov (208) 526-4766 | Source | Mar 9, 2022 |
| Jeffrey C. Fogg | Contact | foggjc@id.doe.gove (208) 526-4958 | Source | Mar 9, 2022 |
| Gregory J. Tomlinson | Contact | tomlingj@id.doe.gov (208) 526-4766 | Source | Feb 8, 2022 |
| Jeffrey C. Fogg | Contact | foggjc@id.doe.gove (208) 526-4958 | Source | Feb 8, 2022 |
Research next steps
- Check the linked forecast or SAM for a confirmed solicitation and current timing.
- Verify whether remaining options may extend performance beyond the current end date.
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.